Stifel Financial Corp X4 Pharmaceuticals, Inc Transaction History

Stifel Financial Corp

$93.2 Billion
Q3 2024

A detailed history of Stifel Financial Corp transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Stifel Financial Corp holds 122,448 shares of XFOR stock, worth $41,632. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,448

Previous 164,267 25.46%

Holding current value

$41,632

Previous $95,000 13.68%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.86 $22,582 - $35,964	-41,819 Reduced 25.46%	122,448 $82,000
Q2 2024 Aug 13, 2024	BUY	$0.58 - $1.47 $45,264 - $114,721	78,042 Added 90.51%	164,267 $95,000
Q1 2024 May 13, 2024	SELL	$0.72 - $1.46 $3,043 - $6,171	-4,227 Reduced 4.67%	86,225 $119,000
Q4 2023 Feb 12, 2024	BUY	$0.61 - $0.99 $6,206 - $10,072	10,174 Added 12.67%	90,452 $75,000
Q3 2023 Nov 13, 2023	SELL	$1.03 - $2.02 $1,068 - $2,094	-1,037 Reduced 1.28%	80,278 $87,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $2.49 $9,989 - $30,333	-12,182 Reduced 13.03%	81,315 $157,000
Q1 2023 May 12, 2023	BUY	$0.8 - $1.22 $9,200 - $14,031	11,501 Added 14.03%	93,497 $81,000
Q4 2022 Feb 13, 2023	BUY	$0.69 - $2.21 $10,124 - $32,427	14,673 Added 21.79%	81,996 $81,000
Q3 2022 Nov 14, 2022	SELL	$0.89 - $1.71 $142 - $273	-160 Reduced 0.24%	67,323 $115,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.91 $1,862 - $4,041	-2,116 Reduced 3.04%	67,483 $65,000
Q1 2022 May 13, 2022	BUY	$1.48 - $2.58 $103,006 - $179,565	69,599 New	69,599 $122,000

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.

Account

Stifel Financial Corp X4 Pharmaceuticals, Inc Transaction History